Navigation Links
Aviir Laboratories Announce National Agreement with Stratose
Date:5/11/2012

IRVINE, Calif., May 10, 2012 /PRNewswire/ -- Aviir Diagnostic Laboratory has entered into a contractual agreement for ancillary diagnostic laboratory testing as a participating provider with Stratose Network and their 8.6 million lives network.

About Stratose

A true pioneer of claims optimization, Stratose (formerly operating as Coalition America, NPPN, OPPN, PlanCare America, 4MOST Health, Qualident and KeyClaims) works to reduce the cost and ensure the best financial results on every medical, dental and workers' compensation claim for insurance carriers, TPAs, HMOs, stop-loss carriers and Labor/Taft- Hartley funds. Through our powerful combination of personal relationships, proprietary data and hands-on claims review, we have delivered a history of savings for our clients—over $10 billion since 1995.

Coalition America, a leader in healthcare cost containment services for medical, dental and workers' compensation claims, is pleased to announce the company and its affiliate brands have been consolidated and rebranded as Stratose. The new brand, including name, logo and web presence, better reflects the company's key market position. The company is able to apply network relationships and proprietary technology to deliver optimal savings on healthcare claims for payors.

The company's new name and brand are founded on a stratified view of claims cost management. Instead of the traditional in- or out-of-network categories, Stratose evaluates all claim types to identify opportunities for savings. "By drilling deeper into these categories, we can better leverage network relationships, creative service solutions and data analytics to deliver the best financial results for everyone involved," Stratose President Tina Ellex says.

"Since 1995, we have ensured the best savings results for payor customers," says Ellex. "We are continuing to drive greater value for our customers as Stratose. We positively impact the industry in terms of job growth, lower healthcare costs and access to quality care."

About Aviir

Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests that will assist in identifying patients that are truly at high risk for the development of a cardiac event.  Aviir's proprietary MiRisk™ and TruRisk™ assessments objectively identify, by a simple blood draw, individuals who are at a high risk of a cardiac event over the next five years.  Aviir's CLIA laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders – including pharmacogenomics and genetic tests. www.aviir.com

"There is currently a significant yet unmet clinical need in the medical community for more effective ways to identify individuals at high risk of a heart attack who are missed by current evaluation methods. Providing an accurate assessment of the patient's overall heart health is the first step in prevention of cardiovascular disease," stated Douglas Harrington, M.D., Chief Executive Officer of Aviir.

"At Aviir, our ultimate goal is to help physicians identify those patients who are at serious risk of experiencing a heart attack but are completely unaware of their precarious condition. Armed with better information, physicians will be able to customize individualized treatment plans with the goal of improving patient therapeutic compliance, reduce their risk of heart attacks, and decrease the overall cost of care," Dr. Harrington added.

Learn more at www.aviir.com
Learn more at www.stratose.com  


'/>"/>
SOURCE Aviir Diagnostic Laboratory
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Aviir Diagnostics Laboratory in Collaboration with Cause;ology Sponsors "Storyland," a Red Carpet Charity Extravaganza in Hollywood
2. Aviir Laboratories Announce National Agreement With MultiPlan
3. Aviir Laboratories Announce National Agreement with Three Rivers Provider Network
4. AIT Laboratories Expands Pharma Services
5. Getting Ready Corporation and Winston Laboratories, Inc. Announce Completion of Merger
6. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Second Quarter Earnings
7. Core Laboratories Joint Venture Agreement Between genae associates, VIBGYOR Scientific Research, Cardiovascular Center Aalst and J.B. Dahm
8. Clontech Laboratories, Inc. Recognizes the 2008 Winners of the Nobel Prize in Chemistry
9. Caraco Pharmaceutical Laboratories Ltd. to Announce Second Quarter of Fiscal Year 2009 Results on October 23, 2008
10. Phenomix and Forest Laboratories to Collaborate on Development and Commercialization of Dutogliptin in Diabetes
11. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):